TBIO - Translate Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.08
-0.02 (-0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 10.10
Open 10.11
Bid 10.16 x 800
Ask 10.16 x 1200
Day's Range 10.00 - 10.92
52 Week Range 4.81 - 14.34
Volume 421,422
Avg. Volume 284,732
Market Cap 514.185M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -2.39
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 19.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Translate Bio Announces Pricing of Public Offering of Common Stock

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $10.00 per share, for aggregate gross proceeds of $90 million, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

  • GlobeNewswire

    Translate Bio Announces Proposed Public Offering of Common Stock

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $90 million of its common stock. Translate Bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

  • 3 Small-Cap Stock Picks From Seth Klarman
    GuruFocus.com

    3 Small-Cap Stock Picks From Seth Klarman

    The guru has high conviction in these stocks Continue reading...

  • GlobeNewswire

    Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has entered into a multi-year strategic manufacturing agreement with Albany Molecular Research, Inc. (AMRI), a best-in-class, global clinical development manufacturing organization, in support of the planned expansion of Translate Bio’s current Good Manufacturing Practices (cGMP) clinical mRNA manufacturing capabilities. Its preclinical programs are focused primarily on targets in additional pulmonary diseases and also include infectious disease targets for vaccine applications. “At Translate Bio, we recognize the importance of developing scalable manufacturing processes in this innovative field and have made this a priority from the inception of our mRNA therapeutic (MRT) platform,” said Ronald Renaud, chief executive officer, Translate Bio.

  • Baupost's Seth Klarman Dives Further Into Translate Bio
    GuruFocus.com

    Baupost's Seth Klarman Dives Further Into Translate Bio

    Guru adds to position in biotech company that focuses on genetic diseases Continue reading...

  • Barrons.com

    Translate Bio Drops Liver- Disease Program. The Stock Is Falling.

    Shares fell more than 8% in premarket trading. The company said it was halting the development program in light of disappointing preclinical studies.

  • GlobeNewswire

    Translate Bio Announces Pipeline Program Update

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it is prioritizing the development of pulmonary disease programs including the ongoing development of MRT5005, its clinical candidate for the treatment of CF, as well as the evaluation of targets in additional pulmonary diseases. Additionally, the Company has decided to discontinue the development of MRT5201, a liver-targeted treatment for OTC deficiency.

  • Barrons.com

    2 Biotech Companies Are Chasing the Next Frontier in Treating Disease. But Will It Work?

    Biotechnology companies are working to develop cutting-edge drugs out of messenger RNA, hoping the technology will be able to deliver the benefits of targeted gene therapy with less risk.

  • GuruFocus.com

    Frazier Management Llc Buys Translate Bio Inc, Kezar Life Sciences Inc

    Investment company Frazier Management Llc (Current Portfolio) buys Translate Bio Inc, Kezar Life Sciences Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Frazier Management Llc. Continue reading...

  • Do Directors Own Translate Bio, Inc. (NASDAQ:TBIO) Shares?
    Simply Wall St.

    Do Directors Own Translate Bio, Inc. (NASDAQ:TBIO) Shares?

    The big shareholder groups in Translate Bio, Inc. (NASDAQ:TBIO) have power over the company. Large companies usually...

  • Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
    Motley Fool

    Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?

    Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.

  • Translate Bio, Inc. (TBIO) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    Translate Bio, Inc. (TBIO) Reports Q2 Loss, Lags Revenue Estimates

    Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -26.67% and -32.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update

    -- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into.

  • GlobeNewswire

    Translate Bio Appoints George Demetri, M.D., to its Board of Directors

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of George D. Demetri, M.D., a physician-scientist at the Dana-Farber Cancer Institute (DFCI), and a professor of medicine at Harvard Medical School to its Board of Directors. “We are honored to have Dr. Demetri join our Board of Directors as we advance our second program into the clinic,” said Ronald Renaud, chief executive officer of Translate Bio.

  • Benzinga

    FDA Lifts Clinical Hold On Translate Bio's Liver Disorder Trial

    Shares of the clinical-stage mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO ), which went public in June 2018, were showing some strength Wednesday.  What Happened Translate Bio said Wednesday ...

  • GlobeNewswire

    Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a single-ascending dose (SAD) Phase 1/2 clinical trial of MRT5201 in adult patients with ornithine transcarbamylase (OTC) deficiency. MRT5201 is a first-in-class treatment designed to directly address the underlying cause of OTC deficiency by providing mRNA encoding the fully functional OTC enzyme in patients with the disease. “We are very pleased to be able to move forward with this first-in-human clinical trial of MRT5201 in patients with OTC deficiency,” said Ronald Renaud, chief executive officer, Translate Bio.

  • MIT gene-therapy spinout raises $6M, enters competitive mRNA field
    American City Business Journals

    MIT gene-therapy spinout raises $6M, enters competitive mRNA field

    Strand Therapeutics hopes to create treatments using messenger RNA or mRNA, which gives instructions to the body’s cells to create proteins. But the young gene-therapy startup thinks it has created a better method than such players as Moderna Inc. and Translate Bio.

  • GlobeNewswire

    Translate Bio to Present at the Jefferies 2019 Healthcare Conference

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will present a corporate overview at the Jefferies 2019 Healthcare Conference in New Yok, NY, on Tuesday, June 4, 2019, at 10:30 a.m. ET. A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

  • GlobeNewswire

    Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update

    -- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 -- Translate Bio.

  • GlobeNewswire

    Translate Bio Announces $47.5 Million Private Placement

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today that it has entered into a securities purchase agreement with several institutional accredited investors for the private placement of 5,582,940 shares of common stock at a purchase price of $8.50 per share, yielding expected gross proceeds of $47.5 million. The private placement is expected to close on or about May 3, 2019, subject to the satisfaction of customary closing conditions. Jefferies and SVB Leerink acted as placement agents to the Company in connection with the private placement.

  • GlobeNewswire

    Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    LEXINGTON, Mass., April 29, 2019 -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially.

  • GlobeNewswire

    Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Robert Plenge, M.D., Ph.D., vice president, research and early development and head of the Inflammation and Immunology Thematic Center of Excellence Unit at Celgene, to its Board of Directors. “On behalf of the Translate Bio team, I’m thrilled to welcome Dr. Plenge to our board of directors,” said Ronald Renaud, chief executive officer, Translate Bio. “My personal mission is to perform discovery research that starts and ends with the patient, and I am grateful to have the opportunity to further pursue this objective by joining Translate Bio’s board of directors,” said Dr. Plenge.

  • GlobeNewswire

    Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the presentation of preclinical data for MRT5201, an mRNA therapeutic designed to treat patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder. The poster presentation, entitled “Treatment of Ornithine Transcarbamylase Deficiency with a Targeted mRNA Therapeutic (MRT),” includes data demonstrating that a functional OTC mRNA encapsulated in a lipid nanoparticle (LNP) was successfully delivered to the liver in a preclinical mouse model of OTC deficiency via intravenous (IV) administration.

  • GlobeNewswire

    Translate Bio Appoints Richard Wooster as Chief Scientific Officer

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Dr. Richard Wooster as chief scientific officer.  Dr. Wooster brings more than three decades of experience in pharmaceutical drug discovery and development and academic research, with expertise in genetics, oncology and translational medicine.  In this role, Dr. Wooster will lead Translate Bio’s scientific strategy and research efforts to support current pipeline programs while also identifying and delivering new programs to expand the Company’s pipeline of mRNA therapeutics.

  • GlobeNewswire

    Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Pasquale (Pat) Sacco as senior vice president of technical operations. Mr. Sacco brings more than 30 years of extensive experience in leading technical operations strategy and execution within the biotech and life sciences industries, including manufacturing, supply chain, quality, engineering, technical sciences, and process development.